Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPA Exposure Misclassification Bias Prevented, HSP Researchers Maintain

This article was originally published in The Tan Sheet

Executive Summary

Hemorrhagic Stroke Project procedures to measure participant recall and product classification prevented misclassification bias related to case and control subjects' phenylpropanolamine (PPA) exposure, Yale University researchers assert.

You may also be interested in...



PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status

An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.

PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status

An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.

PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status

An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel